Cargando…
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
The past decades witnessed the clinical employment of targeted therapies including but not limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic signals. TKIs can be categorized into (i) agents that directly target cancer cells, (ii) normalize angiogenesis or...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154809/ https://www.ncbi.nlm.nih.gov/pubmed/35655707 http://dx.doi.org/10.1080/2162402X.2022.2077898 |